U.S. District Court for the Southern District of California granted Amylin Pharmaceuticals a temporary restraining order (TRO) related to its litigation with respect to the Amylin / Lilly diabetes collaboration agreement.
The TRO restrains Lilly from proceeding with its plans to use the same sales force to sell both exenatide and Boehringer Ingelheim’s competitor drug, linagliptin. The court also enjoined Lilly from disclosing any confidential information about exenatide to any of its sales representatives or employees participating in the marketing, promotion or sale of linagliptin.
Lilly officials said that although they were disappointed with the Court’s decision, they were taking the appropriate steps to comply with the Court’s order, including as it relates to the activities of its sales force, while working to mitigate the impact of any temporary modifications to its diabetes business.
Enrique Conterno, president of Lilly Diabetes, said, “The focus of our business remains on the patients we serve. We seek to offer a broad range of treatment options, including important new therapies, to people with diabetes and their health care providers.”
